ABMC Reports First Quarter 2019 Results

Get in touch

555-555-5555

[email protected]

Topic:

KINDERHOOK, NY / ACCESSWIRE / May 20, 2019 / American Bio Medica Corporation (OTC PINK: ABMC) today announced financial results for the three months ended March 31, 2019.

Chief Executive Officer Melissa A. Waterhouse stated, "New contract manufacturing sales and increased sales of products offered through distribution relationships partially offset lost government sales in the first quarter 2019 when compared to the first quarter 2018. International sales were also down in the first quarter 2019; most of which we believe is due to timing of orders. Expenses remained in line with sales and this allowed us to report a slight improvement in result from operations."

Financial Highlights

Net sales in the first quarter 2019 were $923,000, compared to net sales of $1,041,000 in the first quarter 2018, a decrease of $118,000, or 11.3%.
Operating loss was $174,000 in the first quarter 2019, compared to an operating loss of $206,000 in the first quarter 2018.
Net loss was $240,000 in the first quarter 2019, or $(0.01) per share, compared to a net loss of $267,000, or $(0.01) per share, in the first quarter 2018.

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our product for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2018, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

AMERICAN BIO MEDICA CORPORATION
Condensed Statements of Operations
(unaudited)

	For the three			For the three
	months ended			months ended
	March 31, 2019			March 31, 2018

Net sales	$	923,000		$	1,041,000
Cost of goods sold		617,000			669,000
Gross profit		306,000			372,000

Operating expenses:
Research and development		19,000			25,000
Selling and marketing		113,000			161,000
General and administrative		348,000			392,000
Total operating expenses		480,000			578,000

Operating loss		(174,000	)		(206,000	)

Other expense		(66,000	)		(61,000	)

Net loss before tax		(240,000	)		(267,000	)

Income tax expense		0			0

Net loss	$	(240,000	)	$	(267,000	)

Basic & diluted (loss) / income per common share	$	(0.01	)	$	(0.01	)

Weighted average shares outstanding - basic		32,367,963			29,882,770
Weighted average shares outstanding - diluted		32,367,963			29,822,770

American Bio Medica Corporation
Condensed Balance Sheets

	March 31,			December 31,
	2019 (unaudited)			2018
ASSETS
Current Assets
Cash and cash equivalents	$	54,000		$	113,000
Accounts receivable, net of allowance for doubtful accounts of $36,000 at both March 31, 2019 at December 31, 2018		392,000			452,000
Inventory, net of allowance of $276,000 at March 31, 2019 and $268,000 at December 31, 2018		973,000			1,019,000
Prepaid expenses and other current assets		48,000			29,000
Total current assets		1,467,000			1,613,000
Property, plant and equipment, net		699,000			718,000
Patents, net		121,000			123,000
Other assets		29,000			21,000
Total assets	$	2,316,000		$	2,475,000
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable	$	521,000		$	359,000
Accrued expenses and other current liabilities		440,000			449,000
Wages payable		276,000			278,000
Line of credit		421,000			502,000
Current portion of long-term debt		1,013,000			237,000
Total current liabilities		2,671,000			1,825,000
Long-term debt/other liabilities, net of deferred finance costs		12,000			796,000
Total liabilities		2,683,000			2,621,000
COMMITMENTS AND CONTINGENCIES
Stockholders' Equity:
Common stock		325,000			323,000
Additional paid-in capital		21,421,000			21,404,000
Accumulated deficit		(22,113,000	)		(21,873,000	)
Total stockholders' equity		(367,000	)		(146,000	)
Total liabilities and stockholders' equity	$	2,316,000		$	2,475,000